GROUP

Our research in tumor lymphangiogenesis focuses on the critical role of lymphatic vessels within the tumor microenvironment, particularly in melanoma. Over recent years, it has become evident that tumor-associated lymphatic vessels do more than facilitate fluid drainage; they actively participate in modulating immune responses. Our studies have shown that promoting lymphangiogenesis within tumors enhances T cell infiltration, thereby boosting the effectiveness of immunotherapies. This was notably demonstrated in our 2017 publication in Science Translational Medicine, where we found that increased lymphangiogenesis potentiates immunotherapy outcomes in melanoma models.

We aim to uncover the mechanisms through which lymphatic endothelial cells within tumors regulate immune responses. Our research, indicates that these cells can shape the immune microenvironment, influencing the behavior and infiltration of immune cells. By using both in vivo and in vitro approaches, we investigate how tumor lymphangiogenesis impacts the presentation of antigens and the overall immune landscape within tumors. 

Understanding these complex interactions provides crucial insights into the dual role of lymphatic vessels in both promoting and inhibiting anti-tumor immunity. Our ongoing research strives to elucidate these pathways, aiming to identify novel therapeutic targets and refine strategies to manipulate lymphangiogenesis for improved cancer immunotherapy outcomes.